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Treatment of HIV has long faced the challenge of high mutation rates leading to rapid development of
resistance, with ongoing need to develop new methods to effectively ﬁght the infection. Traditionally,
early HIV medications were designed to inhibit RNA replication and protein production through small
molecular drugs. Peptide based therapeutics are a versatile, promising ﬁeld in HIV therapy, which
continues to develop as we expand our understanding of key protein-protein interactions that occur in
HIV replication and infection. This review begins with an introduction to HIV, followed by the biological
basis of disease, current clinical management of the disease, therapeutics on the market, and ﬁnally
potential avenues for improved drug development.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
The human immunodeﬁciency virus (HIV) is one of the hardest
to control, medically manage, and lethal infectious diseases. HIV is a
major public health problem globally and domestically. The World
Health Organization estimates 37 million people living with HIV or
acquired immunodeﬁciency syndrome (AIDS) worldwide in 2014
with Sub-Saharan Africa accounting for almost 70% of new global
HIV infections [1]. About 44,000 people become infected with HIVus; AIDS, acquired immuno-
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d/4.0/).each year in the United States [2], 350,000 in Asia, 25,000 in the
Middle East&North Africa, 94,000 in Latin America, 88,000 inWest
and Central Europe and North America, 110,000 in Eastern Europe
and Central Asia, and 12,000 in the Caribbean [3]. The CDC esti-
mates about 1.2million people in the United States were living with
HIV at the end of 2012 [4]. Of those people, about 12.8% do not
know they are infected [5]. The number of new infections continues
to rise, particularly in women. HIV treatment is costly. Estimated
cost per patient per year in 2010 was $13,251 [6] in the United
States, impeding HIV treatment in low-resource settings [7].
Therefore, HIV is still one of the hottest topics in basic science,
clinical, and public health research.
Given the magnitude of this pandemic, numerous global efforts
have been gathered to fund research needed for HIV prevention
and treatment. Over $15 billion has been devoted from 2000 to
2014 [8]. The cumulative HIV/AIDS treatment costs from 1996 to
2010 are estimated to be $242 billion. FY2016 US funding for do-
mestic HIV research is $2.8 billion [9]. North America provides the
vast majority of HIV prevention R&D investment (90.9%) [8].
Peptide therapeutics are composed of short amino acid se-
quences that target protein-protein interactions, such as the critical
interaction between the host cell receptors and HIV glycoproteins
required for viral entry into host cells. Peptide based therapies offerAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND
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versatility, high potency, and lower side effects [10]. Peptide/Pro-
tein based therapeutics can bind a domain more speciﬁcally and
effectively than small molecule drugs, as it has larger surface area
and stronger interaction between the target domain and the drug
[11]. It also has fewer medication interactions and toxicity, as it has
more speciﬁc binding to target domains and is metabolized into
nontoxic amino acids [12]. Peptide therapeutics are less likely to
encounter drug resistance, as it requires much more drastic
changes in the viral structure for the virus to develop resistance
against a peptide. However, peptide based therapeutics face chal-
lenges, such as poor in vivo stability and difﬁculty of forming oral
formulations [13]. Currently, two peptide based therapeutics are
being used for HIV treatment: Enfuvirtide, a fusion inhibitor that
binds and blocks conformational change in gp41 [14], and Mar-
aviroc, an entry inhibitor which blocks binding of gp120 to CCR5
[15], with others under investigation for FDA approval.
Treatment of HIV has advanced signiﬁcantly over the past 3
decades. This review will brieﬂy discuss the etiology of HIV [16],
medical management [17], and approved drugs commonly used
[18]. An interesting avenue that has gained much traction for HIV
treatment is the development of HIV virion inhibitor peptides. The
subsequent focus of this review will be to discuss the fundamental
facets of peptide based therapeutics, speciﬁcally those currently in
research. Finally, we provide insight into how these and other novel
therapeutics may change the way we treat HIV. Overall, to be an
effective drug in the treatment of HIV the following are required: 1)
Cost-effective synthesis, 2) high potency with minimal side effects,
3) easy administration to enhance patient compliance, and 4)
educational outreach for disease management and prevention.2. The biological basis of HIV
2.1. Basics of HIV
The origin of HIV has not been clearly understood [19], with
wide speculation that includes its evolution from the simian im-
munodeﬁciency virus [20]. HIV is the virus that can lead to AIDS.
HIV infects and destroys CD4 cells (T cells), and undermines the
human immune system in AIDS. In general, HIV cannot be cured at
present and therefore requires life-long treatment. When not
treated, undermined immunity surrenders to co-infections, such as
HCV (hepatitis C Virus) [21], tuberculosis [22], other sexually
transmitted infections [23], cytomegalovirus [24], and papilloma-
virus [25]. It can also result in age associated morbidities, such as
myocardial infection and cancer [26], and eventually leading to
signiﬁcant patient mortality.
HIV is highly heterogeneous, mutates quickly, and can be latent
for over 10 years, increasing the difﬁculty in prevention and
treatment [27]. Although uncommon, there has been at least one
report of a long-term control for HIV reported using CCR5 Delta32/
Delta32 stem cell transplantation that is resistant to HIV-1 [28,29].
A number of research efforts are ongoing to ﬁnd a cure for HIV
[30,31]. Efforts have focused on ﬁnding treatment and prevention
methods through vaccine and other methods of prophylaxis,
including anti-retroviral drugs like Tenofovir in topical applications
such as vagina gel and ring [32e34], in oral pre-exposure prophy-
laxis [35], and in implants [36]. Oral pre-exposure prophylaxis has
shown effective protection for men who have sex with men by
reducing HIV incidence by 44% [37], but not for heterosexual
women, potentially due to low pill adherence or low drug con-
centrations at the genital tract [38]. Preclinical studies have also
shown signiﬁcant reduction of HIV infection by topical pre-
exposure prophylaxis [39].2.2. Clinical treatment and procedures
Antiretroviral therapy (ART) is the treatment for HIV infection.
Multidrug regimens are used to reduce the progression of disease
to AIDS, occurrence of opportunistic infections, hospitalizations,
and death. There are currently more than 25 antiretroviral medi-
cations available in 5 drug categories (discussed below). Although a
small portion of these are recommended for initial therapy,
continuous assessment of the patient for adverse effects and tox-
icities as well as adherence guides medication choice. Multiple
comparative clinical trials have shown that combination therapy
consisting of 2 nucleoside reverse transcriptase inhibitors and a
third agent from another class is the most effective treatment. The
other classes used in initial treatment are non-nucleoside reverse
transcriptase inhibitors, protease inhibitors, and integrase strand
transfer inhibitors [40].
2.3. Clinical presentation of HIV
HIV infection can present early as a mononucleosis-like illness;
however, many affected individuals are asymptomatic. Estimates
for those who are asymptomatic with HIV are between 10 and 60%,
but it is hard to estimate because most diagnoses are made after a
symptom has led to a work up. Those who have an acute infection,
also known as acute retrovirus syndrome, develop symptoms two
to four weeks after infection. However, incubation of up to 10
months has been reported [41]. Symptoms of acute HIV infection
include fever, lymphadenopathy, sore throat, rash, myalgia,
arthralgia, and headache. None of these symptoms are speciﬁc, but
the presence of these features for an extended duration or with
associated mucocutaneous ulcers is suggestive. Many patients
experience nausea, diarrhea, anorexia, andweight loss. Patients can
present with aseptic meningitis and rarely self-limited encepha-
lopathy. The peripheral nervous system can also be affected.
Opportunistic infections (OIs) usually occur in the later course of
the infection and rarely occur during early infection with the
transient lymphopenia [42]. Oral and esophageal candidiases are
the most commonly occurring OIs. Other OIs in early HIV include
cytomegalovirus (CMV) colitis, proctitis, hepatitis, pneumocystis
jiroveci pneumonia, and cryptosporidiosis.
The chronic period of HIV infection is the time from acute
infection to a CD4 count of <200, and it usually lasts 8e10 years.
AIDS is diagnosed when CD4 reaches <200 cells/mL or with the
presence of an AIDS deﬁning illness, which includes OIs, recurrent
infections, lymphoma of brain, and invasive cervical cancer [43].
Mucocutaneous candidiasis, oral hairy leukoplakia, seborrheic
dermatitis, and herpetic infections occur with greater frequency
when the CD4 cell count is < 200 cells/mL. Eosinophilic folliculitis,
xerosis, prurigo nodularis, molluscum contagiosum, bacillary
angiomatosis, exacerbation of psoriasis, and severe scabies are
associated with AIDS. Anemia, leukopenia, lymphopenia, or
thrombocytopenia is present in 40% of those with CD4 < 200 cells/
mL. Polyclonal hyperglobulinemia is another hematologic
aberration.
2.4. Severity of HIV and associated diseases
OIs usually occur at CD4 levels <200 cells/mL and less often at
levels above that, with approximately 10% of patients developing an
AIDS-deﬁning diagnosis with a CD4 count 200 cells/mL [44].
Disseminated M. avium infection and CMV infections occur pre-
dominantly with a CD4 cell count <50 cells/mL. In the absence of
antiretroviral therapy (ART), the median time to an AIDS-deﬁning
condition in someone with a CD4 cell count < 200 cells/mL is esti-
mated at 12e18 months [45].
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CD4 < 50 cells/mL is 12e18 months. Most patients who die of AIDS-
related complications have CD4 < 50 cells/mL [46]. Above CD4 of
50 cells/mL there is an average of one HIV-related death per 96.7
patient-years of observation as compared with one death per 2.5
patient-years of observation after the CD4 count had fallen below
this level (P < 0.0001) [47].
2.5. Clinical management of HIV
ART is initiated in nearly all HIV infected patients and is usually
started immediately after the initial assessment. Most patients
beneﬁt from the effects of ART regardless of CD4 count. However,
there is a small subset of patients known as “HIV controllers” who
maintain very low HIV RNA levels without ART therapy inwhich no
clear beneﬁt has been demonstrated. The urgency of initiating ART
depends on CD4 count as well as the presence of opportunistic
infections. Patients with CD4 counts in normal ranges, >500 cells/
mL may elect to defer therapy, but they should be counseled as to
the beneﬁts of ART regardless of CD4 count. Starting ART at CD4
counts of <350 cells/mL and especially <200 cells/mL has signiﬁcant
reduction in mortality and morbidity. The higher the CD4 count at
time of initiation the higher the long term CD4 count will be, which
is associated with better long term outcomes [48].
2.6. Morbidity and mortality rates of patients
One study showed a 50% reduction inmorbidity andmortality in
those who initiated ART versus those who did not [40]. The overall
outcome however depended on the level of immunodeﬁciency, as
indicated by CD4 count at the time of treatment initiation. The
hazard ratio for mortality for treated versus untreated are: 0.29 for
CD4 < 100 cells/mL, 0.33 for 100e199 cells/mL, 0.38 for
200e349 cells/mL, 0.55 for 350e599 cells/mL, and 0.77 for
>/ ¼ 500 cells/mL. Another study showed that after 5 years of ART,
the mortality of patients who initiated ART with low CD4 levels and
begins to convergewith thosewith intermediate to high CD4 levels.
When opportunistic infections are present, early initiation of ART
within 14 days leads to a 50% reduction in morbidity and mortality
as compared to late initiation of ART after 14 days.
3. Therapeutic treatments of HIV
3.1. Approved therapeutics on market
More than 25 antiretroviral drugs from 5 therapeutic classes are
available for the management of HIV with over 30 FDA approved in
single and multi-class combination agents [49e51]. Therapeutics
currently on themarket aim to suppress the virus replication below
the level of detection (<50 RNA copies/ml) and to reconstitute
immunity by increasing CD4þ Tcells [52]. These therapeutics can be
classiﬁed into 5 categories based on their mechanisms [53,54]. 1)
Entry inhibitors and 2) integrase inhibitors are two new categories
of anti-retroviral therapeutics [14,55,56]. 3) Nucleoside/nucleotide
reverse transcriptase inhibitors, 4) non-nucleoside reverse tran-
scriptase inhibitors, and 5) protease inhibitors were the targets of
ﬁrst generation HIV therapeutics. These are summarized sche-
matically in Fig. 1.
3.2. Entry/fusion inhibitor
The entry and fusion process of HIV into the host cell is a
complicated process involving several protein-protein interactions
that can be drug targets. Entry of HIV into host cells involves several
viral and host proteins [57], which are reviewed in detail elsewhere[58]. Brieﬂy, the ﬁrst step of HIV entry is attachment e HIV surface
protein gp120 or host proteins integrated in the HIV membrane
typically bind to target cell membranes of CD4þ T cells [59]. The
CD4 transmembrane glycoprotein domain on target T cells attaches
to the CD4 binding site on gp120. This induces a conformational
change in gp120, exposing its co-receptor binding sites [60]. The
co-receptors include but are not limited to CCR5 and CXCR4 on
target T cells, which bind to their respective binding sites on gp120
that are now exposed [61]. Fusion of the viral and host membranes
begins as co-receptor binding induces the second conformational
change in the HIV-1 envelope. As a result, gp41 is exposed and
inserts into the host cell membrane [62]. As mechanisms of entry
and fusion are being elucidated, inhibitors have been discovered
that target different steps in the process.
Entry inhibitors prevent HIV from entering host cells. These
differ from integrase inhibitors, which prevent viral DNA from
integrating into host genome as detailed below [63]. A variety of
compounds including small molecules and antibody-based in-
hibitors have been tested against gp120 and CD4 binding [64e66].
However, this approach has been shown to be ineffective with HIV
isolates [67]. Development of entry inhibitors face this challenge
due to the variability of the viral env gene that codes for gp120 and
gp41 and the variability of co-receptors. With respect to blocking
binding of co-receptors, an FDA approved entry inhibitor, Maraviroc
(approved in 2007), targets CCR5. It is an inverse agonist of CCR5,
which allosterically binds the CCR5 receptor and stabilizes the
inactive conformation of CCR5 [68]. Maraviroc blocks binding of
viral envelope protein gp120 to its CCR5 co-receptor in order to
prevent further steps of membrane fusion necessary for viral entry
[15]. Another prime example of an entry/fusion inhibitor is Enfu-
virtide, a 36 amino acid peptide (approved in 2003) [69e71].
Enfuvirtide binds to a region of the HIV-1 envelope protein gp41
involved in the fusion of viral membrane and host cell membrane
[14].
Although two drugs have been approved by the FDA in this
category, they face challenges and still need to be improved upon.
Maraviroc is only effective for HIV strains that utilize CCR5 for
infection, but not CXCR4-tropic or CXC4/CCR5 bitropic (dualtropic)
HIV strains [72,73]. Inhibition of the CCR-5 co-receptor may inter-
fere with the normal function of CCR5 as a chemokine receptor,
which is required in inﬂammatory responses to infections [73,74].
Enfuvirtide has a very limited window of action when gp41 is
exposed after a conformational change in HIV envelope structure
during the entry/fusion process. As a result, a high concentration of
Enfuvirtidemust bemaintained in the patient [73]. Tomaintain this
concentration, Enfuvirtide requires dosing at 90 mg subcutane-
ously twice daily, which is very difﬁcult to achieve in resource-
limited settings or with good patient compliance. Notwith-
standing, skin sensitivity and side effects commonly associated
with high dosages limit utility. Viralmutation leads to limitations of
Maraviroc and Enfuvirtide due to the nature of their targets.
Therefore, new compounds in development potentially target other
proteins in the entry/fusion process and avoid limitations associ-
ated with CCR5 and gp41 [75e78].
3.3. Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
[79]
NRTIs were the ﬁrst antiretroviral drugs that appeared on the
market [80]. NRTIs are analogs of native nucleoside substrates that
target reverse transcriptase. Reverse transcriptase (RT) is a viral
enzyme that catalyzes the transcription of viral genomic RNA into
double-stranded proviral DNA [81]. The heterodimer of RT is
important for incorporation of the viral genome into the host's
genome. RT has two catalytic activities: DNA polymerase activity,
Fig. 1. HIV proliferation targets and their anti-retroviral drugs. Targets for anti-retroviral drugs include entry inhibition, reverse transcription, genome integration, and protease
inhibition. Contemporary HIV treatments consist of administering multiple drugs (cocktails) to inhibit multiple phases of the HIV life-cycle.
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activity that cleaves the RNA strand in the DNA-RNA duplex formed
after DNA polymerase activity [82]. Seven approved NRTIs are on
the market: Abacavir, Didanosine, Emtricitabine, Lamivudine,
Stavudine, Tenofovir, and Zidovudine [83]. After being phosphor-
ylated by host cellular kinases, NRTIs compete with the natural
substrate - endogenous deoxyguanosine triphosphate [84]. NRTIs
add to and cap the growing viral DNA chain. NRTIs not only target
reverse transcriptase in RNA-dependent DNA synthesis but also
inhibit DNA-dependent DNA synthesis, preventing production of
both () and (þ) strands of viral DNA. Signiﬁcant toxicity is a major
challenge faced by NRTIs, which compromises treatment effec-
tiveness [85]. For example, Stavudine was once part of ﬁrst-line
anti-viral regimens, but then its recommended dosage was
reduced [86] until the use of Stavudine was limited due to its well-
recognized toxicities [87]. Mitochondrial toxicity results from NRTI
inhibition of mitochondrial DNA polymerase and manifests as
myopathy, neuropathy, hepatic failure, and lactic acidosis [88,89].
Current management of side effects is through symptomatic
treatment and reducing dosage regimens [90]. Consequently, drugs
in this pipeline speciﬁcally require mitochondrial toxicity testing in
preclinical phases of development [91].
3.4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) [92]
NNRTIs are the most popular ﬁrst-line HIV treatment regimens
both in the United States and world-wide [93,94]. Some FDA
approved NNRTIs include Delavirdine, Efavirenz, Nevirapine,Etravirine, and Rilvipirine. NNRTIs also target reverse transcriptase
but are allosteric inhibitors. Allosteric binding of NNRTIs to HIV-1
RT [95] induces conformational changes in substrate binding site
of reverse transcriptase, reducing its activity [96]. Challenges to
NNRTIs are a low genetic barrier to drug resistance and cross-
resistance even from a single mutation [97]. Drug resistance is
another major challenge faced by ﬁrst-generation NRTIs, causing
most virologic failures of ﬁrst-line regimens. As a result, NNRTIs are
not recommended for second-line regimens in order to avoid the
risk of resistance [98e100]. Such problems have been partially
improved upon by second-generation NRTIs whose conformational
ﬂexibly allows them to interact with new residues in the binding
pocket or with the main chain residues, which are less likely to
mutate by single side chain residues [101,102]. Consequently,
second-generation NNRTIs can act on ﬁrst-generation NNRTI
resistant HIV strains. In fact, the second-generation NNRTIs, Rilpi-
virine and Etravirine, are second-line drugs in resource-limited
countries. They are indicated in patients for whom Efavirenz or
Nevirapine fail due to their different resistance proﬁles (low cross-
resistance) and suggested high genetic barrier brought on by their
different structures [98,103]. Increasing resistance to both NRTIs
and NNRTIs that decrease drug-RT binding has been observed in
low-income and middle-income countries. Therefore, new drugs
are urgently needed for emerging drug resistant HIV strains [104];
drugs that do not come with major side effects including skin rash,
liver toxicity, and gastrointestinal disturbance [105]. Development
of new NNRTIs is currently in multiple stages, aiming to target
resistant HIV strains and reduce side effects [98].
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Protease inhibitors are a central part of highly active antiretro-
viral therapy (HAART), accounting for 10 out of 26 FDA approved
anti-HIV therapeutics. Protease inhibitors target the viral encoded
aspartyl protease, which is essential for viral maturation and
infectivity [106]. Proteases are important enzymes in many bio-
logical processes and catalyze the hydrolysis of peptide bonds with
high selectivity through activated water molecules or activated
thioesters. HIV Protease in particular is an aspartic protease that
cleaves gag-pol (polypeptide precursors) and gag-polyprotein
precursors into smaller proteins (e.g. reverse transcriptase, RNase
H and integrase) that are modiﬁed and assembled into new viruses
[106,107]. Gag-pol and gag polyprotein precursors are translated
from the viral pol and gag gene [108]. These genes are important for
the formation of gag-pol and gag, which are important precursors
for enzymes synthesis. FDA approved protease inhibitors are
competitive inhibitors to viral proteases. Some FDA approved
therapies include Saquinavir, Indinavir, Nelﬁnavir, Amprenavir,
Lopinavir/Ritonavir, Atazanavir and Fosamprenavir, Tipranavir, and
Darunavir. Saquinavir was the ﬁrst FDA approved drug for the
treatment of AIDS, and it mimics the tetrahedral intermediate of
the proteolytic reaction catalyzed by viral protease [109]. Next
generation protease inhibitors have been developed by modifying
the structure of previous protease inhibitors. Most protease in-
hibitors share similar mechanisms of action by mimicking the
substrate transition state in the proteolytic reaction [106]. They are
competitive inhibitors and all but one (Nelﬁnavir) are peptidomi-
metics of the polyprotein cleavage site of the viral protease [110].
The disadvantage of protease inhibitors include the necessity for
costly life-long treatment, off-target side effects, toxicity, and
adherence [111]. First-generation protease inhibitors were
described as highly peptidic and thus suffer from high instability
and poor bioavailability [112]. Second-generation inhibitors were
designed to address pharmacokinetic stability, side effects, and
drug resistance of ﬁrst-generation protease inhibitors [112]. Side
effects to ﬁrst-generation protease inhibitors include gastrointes-
tinal distress, nausea, diarrhea, abdominal pain, and most
commonly lipodystrophy caused by altering adipocyte metabolism
[110,113]. A signiﬁcant disadvantage is the extensive drug-drug
interactions of protease inhibitors with other drugs, making pro-
tease inhibitors undesirable for patients on other drug regimens
[98].
3.6. Integrase inhibitors [105]
Integrase inhibitors target the integration process of HIV viral
DNA into host DNA. This is a two-step process mediated by the
retroviral enzyme integrase: 1) cut viral DNA and 2) join viral DNA
into host DNA, termed DNA strand transfer [114,115]. Integration is
an essential step in establishing irreversible and chronic infection
[116]. Integrase strand transfer inhibitors (INSTIs) are competitive
inhibitors to integrase that bind to the host DNA binding site and
inhibit DNA strand transfer activity [117,118]. Current integrase
inhibitors target the strand transfer step of the integration process
by binding to the enzyme active site and disengaging it from the
viral DNA [119]. The ﬁrst-generation INSTIs, Raltegravir and Elvi-
tegravir [120] were derived frommodiﬁcation of themonoketo acid
motif of quinolone antibiotics with chelating ability [121,122]. The
development of the ﬁrst INSTI Raltegravir started with the dis-
covery of a b diketo acid moiety with selective inhibitory activity
against DNA strand transfer reactions [123]. Raltegravir had the
disadvantage of a low genetic barrier to mutation and frequent
dosing (twice daily) [98]. Research efforts have been focused on
optimizing interactions between INSTIs and integrase, and it hasresulted in the development of small molecules similar to Ralte-
gravir. For example, Elvitegravir only requires once per day dosing.
However, as Raltegravir-resistant HIV mutations emerge, integrase
inhibitors with mechanisms similar to ﬁrst-generation INSTIs are
likely to fall victim to the mutational competence of HIV [120]. The
second-generation INSTI Dolutegravir was developed as drug
resistant mutations emerged towards ﬁrst-generation INSTIs [55].
Compared to the ﬁrst-generation INSTIs, Dolutegravir improves
bindingwith viral DNA through its more ﬂexible linker region [119],
and has shown fewer drug-drug interactions and side effects [124].
Most frequently reported adverse effects are headache (around 2%)
and insomnia (around 3%) [124] (see Tables 1 and 2).
3.7. Disadvantages of current therapeutics [125]
Drug resistance is a major problem with current HIV thera-
peutics for patients failing therapy and therapy-naive patients due
to the genetic diversity of HIV. 1 to 10 mutations may be generated
every viral replication cycle [54]. Therefore the constant evolution
of HIV demands constant evolution of HIV therapeutics. The prev-
alence of HIV-1 mutated strains that are resistant to one or more
antiretroviral inhibitors or drug classes remains one of the leading
causes of treatment failure among patients with HIV/AIDS
[105,126,127]. NNRTIs are particularly susceptible to small muta-
tions because single nucleotide changes can result in high-level
resistance with only a slight loss of replicative ﬁtness [54]. Resis-
tance to therapeutics undermines the efﬁcacy of HAART as multi-
drug resistant strains evolve. Currently available therapeutics used
in HAART also need to be improved because of serious side effects.
NRTI and NNRTIs have been reported to induce a variety of adverse
effects: neuropathy, lactic acidosis, pruritus, fatigue, nausea, and
myalgia [107,125,128]. Abacavir, for example, causes an immune-
mediated hypersensitivity reaction in 5% of the patients [129]. In-
jection site reactions are the most common adverse events asso-
ciated with Enfuvirtide [130], which requires twice daily
subcutaneous administration due to the high concentration that
needs to be maintained in the body (discussed above in 3.2.). Pro-
tease inhibitors have shown unbearable toxicity [106]: metabolic
syndrome, dyslipidemia, insulin-resistance, lipodystrophy/lipoa-
trophy, and cardiovascular and cerebrovascular toxicity [131e134].
Additionally, they have shown poor oral bioavailability and poor
penetration across the blood brain barrier [52]. Lowering toxicity of
new HIV drugs has been predicted to improve life expectancy and
compliance for many patient groups [135]. Inability of drugs
currently employed in HAART to reach latent viral reservoirs leads
to the necessity for life-long, consistent treatment [136], and the
rapid relapse after any non-compliance [137]. Current drugs have
poor targeting ability and short residence time, contributing to the
latent viral reservoirs [138]. Thus, prolonged and consistent treat-
ment also contributes to the build-up of toxicity and emergence of
resistant HIV strains. Nanotechnologies have been proposed to
solve this problem [138]. Nanotechnologies have been employed to
improve drug oral or i.v. formulation for better bioavailability
[139e143], targeted release [144e146], or long-term action
through sustained release [147]. Among the three nanotechnology
applications in HIV treatment, peptides have been mostly studied
for cell targeting [148e150] and cell penetration [114,151] in de-
livery of small molecules and/or biologics for treatment and pre-
vention of HIV. The synthetic and chemical approach to HIV
treatment has left much to be desired in the ways a technology can
overcome current drug resistances, reduce toxic effects, and
improve ease of administration for wider acceptance, compliance,
and application in global settings, especially in resource-limited
areas [18,152,153]. Short peptides/proteins are a new ﬁeld that
may hold promise for the treatment of HIV, especially for inhibiting
Table 1
Antiretroviral medications.
Medication Target Type Usage Toxicity
Enfuvirtide gp41 Fusion inhibitor Binds & blocks conformational change in gp41 Signiﬁcant
Maraviroc gp120 Entry inhibitor Blocks binding of gp120 to CCR5 hepatotoxic
Abacavir RT NRTI Inhibit DNA-dependent synthesis þ
Didanosine RT NRTI Inhibit DNA-dependent synthesis þþþþ
Emtricitabine RT NRTI inhibit DNA-dependent synthesis þ
Lamivudine RT NRTI Inhibit DNA-dependent synthesis þ
Stavudine RT NRTI Inhibit DNA-dependent synthesis þþþþ
Tenofovir RT NRTI Inhibit DNA-dependent synthesis þ
Zidovudine RT NRTI Inhibit DNA-dependent synthesis þþ
Zalcitabine RT NRTI inhibit DNA-dependent synthesis þþþþ
Raltegravir Enzyme active site Integrase inhibitor Inhibit DNA strand transfer activity Adverse effects
Elvitegravir Enzyme active site Integrase inhibitor Inhibit DNA strand transfer activity Adverse effects
Dolutegravir Enzyme active site Integrase inhibitor Inhibit DNA strand transfer activity Adverse effects
Efavirenz RT NRTI & NtRTI Induce conformational change of RT Toxic effects to CNS
Saquinavir Aspartyl protease Protease inhibitor Viral protease inhibitor GI toxicity
Ritonavir Aspartyl protease Protease inhibitor Viral protease inhibitor GI toxicity
Darunavir Aspartyl protease Protease inhibitor Viral protease inhibitor GI toxicity
Indinavir Aspartyl protease Protease inhibitor Viral protease inhibitor GI toxicity
Tipranavir Aspartyl protease Protease inhibitor Viral protease inhibitor GI toxicity
Fosamprenair Aspartyl protease Protease inhibitor Viral protease inhibitor GI toxicity
Nelﬁnavir Aspartyl protease Protease inhibitor Viral protease inhibitor GI toxicity
Atazanavir Aspartyl protease Protease inhibitor Viral protease inhibitor GI toxicity
Lopinavir Aspartyl protease Protease inhibitor Viral protease inhibitor GI toxicity
Amprenavir Aspartyl protease Protease inhibitor Viral protease inhibitor GI toxicity
þþþþ Strongest association with mitochondrial toxicity, þweakest association with mitochondrial toxicity; Enfuvirtide has common adverse events which include pain,
erythema, pruritus, and induration. Central nervous system (CNS) toxicity involves abnormal mood, delusions, and insomnia; Gastrointestinal toxicity (GI) includes abdominal
pain, nausea, emesis, diarrhea; Adverse effects: nausea, dizziness, headache, insomnia, and fatigue [271,272].
Table 2
Peptide inhibitors.
Peptide Amino acid sequence Type Target Reference
Anti-gp120 DGGNSNNESEIFRPGGGDMRDN Entry inhibitor HIV-1/gp120 [162]
Anti-CCR5 YQVSSPIYDINYYTSEPCQKINVKQIAA Entry inhibitor Co-receptor CCR5 [163]
PIE12-trimer HPXXCDYPEWQWLCXXELGK Entry inhibitor HIV gp41 N-trimer pocket [159]
PAW GTKWLTEWIPLTAEAEC RT inhibitor HIV-1 RT [179]
G12 GI-p-benzoylphenylalanine-FVSL Protease inhibitor ε-amino group of Lys 14 of HIV protease [205]
E1P47 WILEYLWKVPFDFWRGV Entry inhibitor HIV-1 Fusion Peptide [168]
p7 KETWETWWTE RT inhibitor Dimerization of RT [182]
Apam (2)-Tyr-Glu-T (4)-OH RT inhibitor HIV-1 protease dimer interface [180]
Vpr 57-71 VEAIIRILQQLLFIH RT inhibitor HIV-1 IN & RT [183]
Vpr 61-75 IRILQQLLFIHFRIG RT inhibitor HIV-1 IN & RT [183]
NYAD-1 HITFEDLLDYYGP-NH2 Gag inhibitor HIV-1 Gag polyprotein [245]
Vif peptide LITPKKIKPPLPSVT Vif inhibitor HIV-1 Vif [234]
p27 PQITLRKKRRQRRRPPQVSFNFCTLNF Protease inhibitor WT & PI resistant HIV-1 protease [190,207]
Tetrameric peptide 10 ((ILPWKWPWWPWPP)2K)2K-NH2 Integrase inhibitor HIV-1 integrase [270]
Tetrameric RIN-25 ((ILPWKWPWWPWPP)2K)2K Integrase inhibitor HIV-1 integrase [209]
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greater afﬁnity than small molecules to these weak binding
pockets.
4. Targets of peptide inhibitors [154e156]
4.1. Peptide inhibitors
Peptide inhibitors share similar targets to currently approved
therapeutics and have also been applied to other targets. The tar-
gets that have been investigated include entry/fusion, reverse
transcriptase, protease and integrase. HIV therapeutics are now
generally discovered through 1) high-throughput compound
screening with virus-speciﬁc assays, 2) optimization of lead com-
pounds, and 3) rational drug design based on the structure of viral
proteins [54]. Peptide inhibitors are usually designed based on 1)
viral or host protein targets and protein-protein interactions and 2)
screening of peptide libraries. Structures are then subject to virus
speciﬁc assays. Peptide/protein inhibitors hold great promise toimproving upon the drug-resistance of small molecular antiviral
therapeutics because resistance to macromolecules like peptides
and proteins requires evolutionary mutations or co-receptor
changes that are a lot less likely than single nucleotide changes in
NNRTI-resistant mutations [111,125,157e159]. Thanks to Qureshi
et al., a database of HIV inhibiting peptides has been developed and
is constantly updated [160]. Peptides in development, summarized
in previous reviews and databases [156,160], are summarized
below according to their targets.
4.2. Entry and virus cell fusion [125]
Peptide inhibitors that target the entry process inhibit one or
more key proteins including gp41, gp120, coreceptors (CCR5,
CXCR4, APJ), and CD4 [77,111,125]. Currently as the biological un-
derstanding of the entry process increases, a number of design and
modiﬁcation schemes have been presented, and a large number of
prospective fusion peptides have emerged [161]. The most prom-
ising peptides and proteins that inhibit the entry and fusion process
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hibitors by binding viral or host proteins. Antibodies include anti-
gp120 monoclonal antibodies and smaller derivatives [162,163],
anti-CD4 antibodies, and anti-CCR5 monoclonal antibodies. Direct
inhibitors include soluble gp120 receptors as gp120 inhibitors,
synthetic and natural gp41 inhibitors [159,164e166], synthetic
anti-CCR5 peptides [167], CXCR4 inhibitors, and multi-functional
inhibitors (lectins and defensins) [125]. Another class of peptide
inhibitors targeting the entry/fusion process mimics the E2 enve-
lope glycoprotein and the NS5A phosphoprotein from GB virus C
(GBV-C), which has been shown to inhibit HIV entry [168]. Mole-
cules under investigation share similar limitations to the peptide
fusion inhibitor Enfuvirtide - poor bioavailability [169,170] and high
cost of production [171,172]. Some protease inhibitors showadverse
side effects, such as an inﬂammatory response induced by anti-
CCR5 peptides [125,172]. High dosage is needed for current anti-
gp120 antibodies [173]. Due to such limitations, microbicides
were used as an alternative to oral administration or injection for
several promising peptide entry inhibitors (T20 (Enfuvirtide) [174],
T1249 [175], L0644 [176] and Sifuvirtide [177]).
4.3. Reverse transcriptase (RT)
Peptide mimics of reverse transcriptase subunits have been
found to inhibit heterodimerization and conformational changes
during the formation of reverse transcriptase [81,178e181]. Ex-
amples include residues 395e404 of RT [182] and Paw [179]. Pep-
tide mimics of other RT binding viral proteins, such as a Vpr
protein-derived peptide, also hold promise as peptide inhibitors
[183]. Other peptide inhibitors for RT include peptides derived from
ribonuclease [184,185], polyarginine transporter molecules [186],
N-methylated peptides that bind RNA [187], protein targeting RTC
[188], and anti-fungal peptides [189]. Similarly to protease and
integrase peptide inhibitors, RT peptide inhibitors also face the
problem of low potency (high IC50 values) and thus have not
advanced to in vivo evaluation or clinical studies. There are much
fewer publications on RT peptide inhibitors than on entry peptide
inhibitors, integrase peptide inhibitors, and protease peptide in-
hibitors, which is partially due to the success of small molecules in
inhibiting RT.
4.4. Protease inhibitors
Peptide inhibitors have also been shown to inhibit protease
dimerization. The dimerization interface of protease is created by
the conserved active site triad, Asp-Thr-Gly, and four antiparallel
beta sheets of the C-terminus and N-terminus of each monomer
[190e192]. Short peptides were synthesized according to the N and
C terminus of the protease, which prevents the protease monomer
from associating with another monomer. As dimerization is
necessary for proteolytic activity, prevention of dimerization
effectively inhibits protease activity [178,193]. To improve upon the
weak inhibitory potency of C-terminus and N-terminus mimics
[194e196], ﬂexible linkers and rigid scaffolds have been used, as
well as side chain tethering (intercalating “molecular tongs”)
[113,197e200] and terminal modiﬁcation with lipophilic groups
and alkyl chains [201e204]. Interfacial peptides can also serve as
irreversible inhibitors by covalently associating with protease
[205,206]. Another type of peptide inhibitor that targets dimer-
ization is the fusion of N-terminal HIV-1 protease peptide with cell
permeable domain of the HIV-1 Tat protein, which is the trans-
activator of the virus [190,207]. Peptide-based protease inhibitors
require modulation to overcome the weak binding potency of in-
hibitors with the protein-protein interaction interface, which in-
creases the complexity of drug design involving optimization ofcovalent modiﬁcations of peptide chains [198]. Prevalence of and
similarities between families of proteases in the human body in-
creases the standard for protease inhibitors in recognizing and
inhibiting viral proteases and penetrating cell membrane [208].
Meanwhile, peptides show great promise as protease inhibitors
because of their versatility in targeting parts of proteases and
protease-binding proteins other than the catalytic domain and
binding sites that are similar between human and viral proteases.
4.5. Integrase inhibitors
Protein-protein interactions involving integrase, including
integrase dimerization and integrase-substrate and allosteric
cofactor interactions have been investigated for peptide inhibitor
designs [81,105,209]. The ﬁrst group of peptides was derived from
the dimer surface of integrase inhibitors with the intent to disrupt
integrase inhibitors' dimerization or to inhibit their enzymatic ac-
tivity [178,209e215]. Lead peptides were then improved in design
with D-amino acids to prevent degradation. Advancement in the
understanding of protein-protein interactions involving integrase
has enabled more targeted drug designs. The second group of
peptides were derived from integrase inhibitor-binding proteins in
order to inhibit integrase inhibitor interaction with host proteins
(cofactors such as LEDGF/p75 [216e219]) [220] or viral proteins
[221e223], such as viral reverse transcriptase [224], Vpr protein
[183], and Rev protein. Besides designing inhibitory peptides from
integrase inhibitors and integrase inhibitor-binding proteins,
inhibitory peptides have been found through screening of phage
display libraries or with yeast two-hybrid systems. Antimicrobial
peptides showing integrase inhibitory activities include Indolicidin,
a host cell defense tridecapeptide [225]. Protein-protein interaction
inhibitors, including dimerization inhibitors, have been shown to
be relatively week inhibitors with IC50 in the range of 1e250 mM
[209]. The advantage of macromolecules, such as peptides and
proteins, over small molecule drugs is that they can potentially be
optimized in designing shallow binding pockets, such as protein-
protein interactions. Since current lead peptide inhibitors are only
tested in vitro assays, potency needs to be optimized before in vivo
assays and clinical studies. Peptide interface inhibitors of protease
and integrase have been studied since the last century [193,196]
from biochemical standpoints but have yet to come close to
testing in animals. As interface inhibitors need to bind the target
protein tightly enough to outcompete its natural binding partner, it
is challenging to design peptides thatmimic the binding partner yet
have signiﬁcantly higher binding afﬁnity to achieve clinically
meaningful potency [226]. Alternatively, next generation designs of
small molecule drugs have been proposed using peptides as start-
ing points [209,222,223].
4.6. Others
Other HIV inhibitors include those designed based on other
speciﬁc targets [227e229] and through screening of existing pep-
tide libraries [230e233]. Target-based design of HIV inhibitors have
involved targeting: 1) interactions between viral Tat protein and
host TAR protein [227,228], 2) polyproline interfaces of viral
infectivity factor for the multimerization of viron infectivity factor
proteins [234], 3) the budding of HIV after replication in host cells
[235,236], 4) viral gene expression [237], 5) viron maturation (gag-
derived peptides [229], inhibiting gag processing), 6) multi-stage
infectivity (CD4 antigen-based anti-receptor peptides [238]), 7)
unidentiﬁed GBV-C E2 protein [239,240], 8) syncytium formation
[241,242], 9) viral Vpr and rev proteins [243,244], 10) viral assembly
[245e247], and 11) alpha-glucosidase [248]. Antimicrobial peptides
have been derived from a variety of species, such as amphibians, or
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[230]. They have been shown to inhibit HIV infections of T cells and
disrupt HIV envelope and viral core proteins [230e233]. A prime
example is caerin antimicrobial peptides [230]. Anti-HIV antimi-
crobial peptides have been developed in vitro thus far, and more
research is needed to evaluate the suppressing or enhancing effects,
as well as chemotactic effects of antimicrobial peptides on the
native immune system [249]. Physiological toxicity is a major
drawback antimicrobial peptides [250].
4.7. Promising strategies in development
As drug resistance continues to emerge, new drug classes
(integrase and virus entry inhibitors) and new drugs in old classes
(NRTI and NNRTIs) that are active against drug-resistant HIV strains
are needed to combat drug-resistant HIV strains [251,252]. Because
of viral resistance to integrase strand transfer inhibitors targeting
the catalytic site, new generations of HIV inhibitors not based on
the catalytic triad, such as allosteric integrase inhibitors (ALLINIs),
can target INSTI-resistant viruses [105].
Peptide inhibitor design starts from designing peptides ac-
cording to certain regions of viral or host proteins, screening in
peptide libraries for anti-HIV activities, and screening of the entire
span of viral proteins and protein-protein interactions that can
generate lead peptides needed to be reﬁned [183]. For integrase
inhibitors, it is easier to design peptide inhibitors than small
molecule inhibitors for preventing protein-protein interactions
because it is easier to use peptides to mimic existing binding sites
[209]. Limitations faced by peptide inhibitors before clinical trials
include bioavailability, instability, and high cost of production [111].
Peptides are polar compounds, and cell penetration is necessary for
most targets except for entry/fusion inhibitors, which requires
lipophilicity [11]. The inability to penetrate cell membranes has
halted development of many peptide based therapeutics [245]. Cell
penetration can be aided by nanotechnologies discussed earlier in
the review, including conjugating peptides with a cell penetrating
peptide derived from HIV Tat protein [253]. Peptide/protein drugs
are very prone to degradation in vivo and therefore generally are
susceptible to GI ﬁrst pass metabolism [11]. This instability of
peptide/protein drugs and poor oral bioavailability necessitates
subcutaneous, intramuscular, or intravenous delivery. Using pep-
tides as a starting point, small molecule drugs can be designed for
systemic administration [254]. Alternatively, peptide/protein in-
hibitors can be used in topical applications, such as peptide/protein
based microbicides [125]. Unlike other small molecules, peptide
fusion inhibitors may be adsorbed slowly and could extend their
half-life at mucosal sites [168]. The high cost of production due to
costly expression systems in bacteria, yeast, or mammalian systems
has been one of the major limitations for several promising peptide
inhibitors [125].
5. Discussion
HIV therapeutics have developed signiﬁcantly over the past few
decades. Clinically, decreasing the spread of HIV begins with edu-
cation. Rationale approaches given the socioeconomic and societal
considerations of the patient population encourage the use of
preventative approaches such as pre exposure prophylaxis (PrEP).
Once infection is established, the current standard of care is com-
bination of ART initiationwith two nucleoside reverse transcriptase
inhibitors and a third agent from a different drug category. This is
followed by monitoring for any adverse events, toxicity, adherence
issues, or drug resistance and making appropriate changes in
medication.
The primary deﬁciencies of current HIV therapeutics indevelopment are administration difﬁculties, adverse effects, and
emerging resistance. Peptide and protein drugs are an exciting new
ﬁeld inmedicinal chemistry, as evident bymore than 1000 peptide-
based drugs that have reached the market [255]. The development
of peptide based inhibitors of HIV infection have the beneﬁt of
higher potency, higher selectivity, lower toxicity, fewer side effects
than small molecules, predictable metabolism, shorter time to
market, lower attrition rates, standard synthetic protocols, targeted
designs to a broad range of targets, lower accumulation in tissues,
higher chemical and biological diversity, and lower chances of
developing drug resistance [11,256].
An interesting approach to improve target cell interaction is to
increase the epitope presentation of peptide based drugs [257]. In a
recent study based on angiogenesis for the treatment of peripheral
artery disease, a novel self-assembling peptide therapeutic, termed
SLanc, has shown the potential for improved angiogenesis [258].
The potential mechanism of action is increased peptide epitope
presentation that enhances angiogenic receptor activation and
signaling [258]. Similarly, the potential for self-assembling peptides
to present inhibitory signals at high epitope density on the surface
of T cells or virons, may allow for smaller dosing regimens and
higher efﬁcacy [259]. One useful application for self-assembling
peptides is in vaginal microbicide for prevention of HIV [260]. Us-
ing a self-assembling peptide hydrogel to present inhibitory signals
reduces dosing and costs, which are signiﬁcant challenges to be
solved in HIV microbicide development [261]. Another strategy is
conjugating self-assembling peptides with mimetic peptides
derived from the viral envelope proteins or receptors that
neutralize HIV particles [262,263]. Self-assembling peptides con-
jugated with mimetic peptides in vivo can potentially bind and
aggregate HIV particles. The third potential of conjugation of a self-
assembling peptide with HIV peptide inhibitors involves using self-
assembling peptide to improve bioavailability and stability, as
shown in PEGylation of peptide inhibitors [49,264]. Such conjuga-
tion may protect peptide inhibitors from rapid degradation and
clearance from the circulation by self-assembly. Conjugation of
small molecule and peptide drugs to polymers may allow slow and
constant release of drugs and avoid spikes in the blood plasma
[265]. Slow, steady release can be further tuned by the length and
self-assembling properties of peptide scaffolds and results in
decreased dosage and improved patient compliance [266e269].
Overall, conjugation of self-assembling peptides presents an op-
portunity to signiﬁcantly improve major limitations of peptide-
based drugs, including unsatisfactory pharmacokinetic properties,
rapid metabolism, poor solubility, and poor bioavailability.
6. Conclusion
HIV is a difﬁcult disease to manage with high rates of morbidity
and mortality. There are 37 million infected individuals worldwide
and 12.8% of them do not know they are infected. Given the
magnitude of this pandemic numerous research efforts looking for
prevention and treatment of HIV are made with $15 billion being
devoted from 2000 to 2004. We aimed to discuss HIV viron in-
hibitor peptides as a potential effective therapeutic. HIV requires
life-long treatment. ART is the treatment for HIV: 2 nucleoside
reverse transcriptase inhibitors and a third agent from another
class is the most effective treatment. The other classes used in
initial treatment are non-nucleoside reverse transcriptase in-
hibitors, protease inhibitors, and integrase strand transfer in-
hibitors. HIV can present as an early mononucleosis-like illness or
can be asymptomatic early on. Chronic infection occurs from the
time of acute infection to a CD4 count of <200 cells/mL. AIDS is
deﬁned as a CD4 count of less than 200 cells/mL or the presence of
an AIDS deﬁning illness.
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assessment regardless of CD4 count. More than 25 antiretroviral
from six therapeutic classes are available. A variety of compounds
have been tested against gp120 and CD4 binding. Development of
these compounds faces challenges due to the variety in the env
gene that codes for gp120 and gp41 and the variety of co-receptors.
With regards to co-receptors, CCR5 is blocked by Maraviroc, which
blocks binding of gp120 to CCR5. Enfuvirtide binds gp41. These are
the two FDA drugs approved as entry/fusion inhibitors and each
have their own limitations. Novel agents are looking to target
proteins other than CCR5 and gp41. NRTIs were the ﬁrst antire-
troviral drugs available. These agents are complicated by associated
toxicity. NNRTIs are the most utilized ﬁrst line treatment and are
faced by the challenge of a low genetic barrier to drug resistance.
Protease inhibitors are complicated by being costly and having side
effects, as well as drug-drug interactions. Integrase inhibitors block
the incorporation of HIV DNA to host DNA. Drug resistance is one of
the major challenges to current therapeutics. There are also a va-
riety of toxicities and side effects. They lack good targeting ability
and have a short residence time. Short peptides used to inhibit
newly discovered protein-protein interaction targets are an area of
research that holds promise for novel therapeutics.
Peptide inhibitors share similar targets to currently approved
therapeutics as well as other targets. They hold promise on
improving drug resistance issues. Many entry and fusion inhibitor
models exist for peptides. There are fewer publications on peptide
reverse transcriptase inhibition. Peptide inhibitors for integrase
inhibition have been investigated. For integrase inhibitors, peptide
inhibitors are better than small molecules to target protein-protein
interactions. They are limited by bioavailability, instability, and high
cost of production.
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